CDER Drug Risk Information

OMB Number
Expiration Date

CDER Health Information Survey
You have accessed this survey through a certain FDA web-based publication. Your response to this brief
survey should take only a few minutes of your time and should relate to the specific FDA
web-based publication. Completion of the survey is voluntary, and your responses will be kept confidential
and anonymous.

1) What is your overall impression of the format or presentation of the information in this FDA
publication on a scale from 1 to 5 where 1 is poor, 3 is average and 5 is excellent?

Easy to read
Easy to find
what I need
Organization of
information
Font and font
size
Length

Poor
1
m

2
m

Average
3
m

4
m

Excellent
5
m

m

m

m

m

m

m

m

m

m

m

m

m

m

m

m

m

m

m

m

m

2) What about the format or presentation of this FDA publication do you like?

______________________________________________________________________________________
______________________________________________________________________________________
________________________________________________

3) What about the format or presentation of this FDA publication do you dislike?

______________________________________________________________________________________
______________________________________________________________________________________
________________________________________________

4) What is your overall impression of the content of this FDA publication on a scale from 1 to 5
where 1 is poor, 3 is average and 5 is excellent?

Relevance to

Poor
1
m

2
m

Average
3
m

4
m

Excellent
5
m

your specialty or
area of expertise
Understandable
Timeliness
Helpful
Amount of
background
information

m
m
m

m
m
m

m
m
m

m
m
m

m
m
m

m

m

m

m

m

5) Do you ever share the information (content) of this publication with others?
m Yes
m No
6) How do you share it with others?

______________________________________________________________________________________
______________________________________________________________________________________
________________________________________________

7) Have you sought additional information on a particular topic after reading the FDA
communication?
m Yes
m No
8) Which sources did you consult for additional information?

______________________________________________________________________________________
______________________________________________________________________________________
________________________________________________

9) If you are a prescriber, did you find FDA’s communication of information helpful in making
treatment decisions for your patients?
m Yes
m No
m Not A Prescriber
10) If you are a prescriber, have you changed prescribing behavior based on the information you
received from the FDA?
m Yes
m No
11) Which, if any, describes the change in your prescribing behavior?
q Provide additional risk information to patients
q Spend additional time counseling patients
q Monitor patients differently

q Prescribe a different drug
q Other (please specify)

If you selected other, please specify
______________________________________________________________________
12) Which FDA publication did you select that brought you to this survey?
m Early Communication about an Ongoing Safety Review (Early Communications)
m Public Health Advisories (PHAs)
m Information for Healthcare Professionals (HCP sheets)
m Drug Safety Newsletter
13) Was it easy to find this FDA publication?
m Yes
m No
14) What difficulties did you encounter accessing this FDA publication?

______________________________________________________________________________________
______________________________________________________________________________________
________________________________________________

15) Through which other ways or sources do you receive or access drug safety information?
q Subscription to FDA materials (e.g., MedWatch E-list, FDA email updates, other)
q Internet Searches
q Newspaper articles
q Word of mouth
q Professional Newsletter
q All of the above
q Other (please specify)

If you selected other, please specify
______________________________________________________________________
16) Please specify:
q Early Communication about an Ongoing Safety Review (Early Communications)
q Public Health Advisories (PHAs)
q Information for Healthcare Professionals (HCP sheets)
q Drug Safety Newsletter
q Other (please specify)

If you selected other, please specify
______________________________________________________________________
17) My occupation is:
m Medical doctor

m Pharmacist
m Nurse
m Nurse Practitioner
m Dentist
m Other (please specify)

If you selected other, please specify
______________________________________________________________________
18) My work setting is
m Solo practitioner
m Group practice
m Hospital/medical center
m Other (please specify)

If you selected other, please specify
______________________________________________________________________
19) My age is:
m Less than 18 years
m 18-24 years old
m 25-34 years old
m 35-49 years old
m 50-64 years old
m 65 years old or older
m No answer

Thank you for providing feedback on the various communication tools used by the FDA to
communicate drug safety information to the public. FDA continuously evaluates its
communication efforts to enhance their accessibility and effectiveness. Your response to this brief
survey will help us improve our communication about drug safety issues. Please click below to
submit your survey responses.